Findings

What do systematic reviews say?

6 questions · 6 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 1 · 16.7%Moderate 3 · 50%High 1 · 16.7%

Platinum‐containing chemotherapy vs chemotherapy without platinum

Anaemia (grade ≥ 3) · early triple‐negative breast cancer

Platinum‐containing chemotherapy probably leads to higher anaemia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).

1 finding from 1 review

Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
RR 8.2 [5.66, 11.89]
19 studies · 4757 participants
Moderate

Intervention not reported

Anaemia grade 3 or 4 (safety population) by type of platinum agent in platinum regimen · women with metastatic breast cancer

The intervention leads to higher anaemia grade 3 or 4 (safety population) by type of platinum agent… (high certainty).

1 finding from 1 review

Platinum‐containing regimens for metastatic breast cancer 2017 · Cochrane Headline outcomes only
RR 1.72
7 studies · 1441 participants
High

Summary of findings 2: PLD alone vs other conventional chemotherapy

Anaemia (grade ≥ 3) · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings 2: PLD alone changes anaemia (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1968 participants
Very low

Summary of findings 1: PLD with chemotherapy vs PLD alone

Anaemia (grade ≥ 3) · recurrent platinum‐resistant EOC

Summary of findings 3: PLD with chemotherapy probably leads to higher anaemia (grade ≥ 3) compared with PLD alone (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 2.38 [1.46, 3.87]
2 studies · 785 participants
Moderate

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Anaemia (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings 1: PLD with chemotherapy probably leads to higher anaemia (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 1.37 [1.02, 1.85]
5 studies · 1961 participants
Moderate

Intervention not reported

Anaemia grade 3 or 4 (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)

The intervention may leads to higher anaemia grade 3 or 4 (safety population) (low certainty).

1 finding from 1 review

Platinum‐containing regimens for triple‐negative metastatic breast cancer 2020 · Cochrane Headline outcomes only
RR 3.8
5 studies · 843 participants
Low